VYVANSE

Peak

lisdexamfetamine dimesylate

NDAORALTABLET, CHEWABLE
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
60/100
Clinical Trials
18

Mechanism of Action

dextroamphetamine. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in ADHD and BED is not known.

Clinical Trials (5)

NCT06847399Phase 2Recruiting

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Started Sep 2025
105 enrolled
Obesity and OverweightBinge Eating Disorder
NCT04866043N/ACompleted

Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder

Started Jun 2019
150 enrolled
Binge-eating Disorder
NCT01657019Phase 3Completed

Open Label Extension in Adults With Binge Eating Disorder (BED)

Started Aug 2012
604 enrolled
Binge Eating Disorder
NCT01552915Phase 4Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Started Apr 2012
464 enrolled
Attention-deficit/Hyperactivity Disorder
NCT01552902Phase 4Completed

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

Started Apr 2012
549 enrolled
Attention-deficit/Hyperactivity Disorder